Medicated intrauterine devices for contraception and their therapeutic effects

References

• Luukkainen T, Allonen H, Haukkamaa M, Lähteenmäki P, Nilsson CG, Toivonen J. Five years’ experience with levonorgestrel-releasing IUDs. Contraception33(2), 139–148 (1986).
   PubMed Web of Science ®Google Scholar
• Sivin I. Extrauterine pregnancies and intrauterine devices reassesed. In: Bardin CW, Mishell DR Jr (Eds). Proceedings from the Fourth International Conference on IUDs. Butterworth-Heinemann, MA, USA, 195–209 (1994).
   Google Scholar
• Luukkainen T, Pakarinen P, Toivonen J. Progestin-releasing intrauterine systems. Semin. Reprod. Med.19(4), 355–363 (2001).
   PubMed Web of Science ®Google Scholar
• Pakarinen P, Toivonen J, Luukkainen T. Therapeutic use of the LNG IUS, and counseling. Semin. Reprod. Med.19(4), 365–372 (2001).
   PubMed Web of Science ®Google Scholar
• Jensen JT. Contraceptive and therapeutic effects of the levonorgestrel intrauterine system: an overview. Obstet. Gynecol. Surv.60(9), 604–612 (2005).
   PubMed Web of Science ®Google Scholar
• Munuce MJ, Nascimento JA, Rosano G, Faundes A, Bahamondes L. Doses of levonorgestrel comparable to that delivered by the levonorgestrel-releasing intrauterine system can modify the in vitro expression of zona binding sites of human spermatozoa. Contraception73(1), 97–101 (2006).
   PubMed Web of Science ®Google Scholar
• Luukkainen T, Lähteenmäki P, Toivonen J. Levonorgestrel-releasing intrauterine device. Ann. Med.22(2), 85–90 (1990).
   PubMed Web of Science ®Google Scholar
• Toivonen J, Luukkainen T, Allonen H. Protective effect of intrauterine release of levonorgestrel on pelvic infection: three years’ comparative experience of levonorgestrel- and copper-releasing intrauterine devices. Obstet. Gynecol.77(2), 261–264 (1991).
   PubMed Web of Science ®Google Scholar
• Suhonen S, Haukkamaa M, Jakobsson T, Rauramo I. Clinical performance of a levonorgestrel-releasing intrauterine system and oral contraceptives in young nulliparous women: a comparative study. Contraception69(5), 407–412 (2004).
   PubMed Web of Science ®Google Scholar
• Lähteenmäki P, Luukkainen T. Return of ovarian function after abortion. Clin. Endocrinol. (Oxf.)8(2), 123–132 (1978).
   PubMed Web of Science ®Google Scholar
• Nilsson CG, Lähteenmäki P. Recovery of ovarian function after the use of a d-norgestrel-releasing IUD. Contraception15(4), 389–400 (1977).
   Google Scholar
• Belhadj H, Sivin I, Diaz S et al. Recovery of fertility after use of the levonorgestrel 20 µg/d or Copper T 380 Ag intrauterine device. Contraception34(3), 261–267 (1986).
   PubMed Web of Science ®Google Scholar
• Pakarinen P, Toivonen J, Luukkainen T. Randomized comparison of levonorgestrel- and copper-releasing intrauterine systems immediately after abortion, with 5 years’ follow-up. Contraception68(1), 31–34 (2003).
   PubMed Web of Science ®Google Scholar
• Heikkilä M. Puerperal insertion of a copper-releasing and a levonorgestrel-releasing intrauterine contraceptive device. Contraception25(6), 561–572 (1982).
   PubMed Web of Science ®Google Scholar
• Heikkilä M, Haukkamaa M, Luukkainen T. Levonorgestrel in milk and plasma of breast-feeding women with a levonorgestrel-releasing IUD. Contraception25(1), 41–49 (1982).
   PubMed Web of Science ®Google Scholar
• Heikkilä M, Luukkainen T. Duration of breast-feeding and development of children after insertion of a levonorgestrel-releasing intrauterine contraceptive device. Contraception25(3), 279–292 (1982).
   PubMed Web of Science ®Google Scholar
• Heikkilä M, Nylander P, Luukkainen T. Body iron stores and patterns of bleeding after insertion of a levonorgestrel- or a copper-releasing intrauterine contraceptive device. Contraception26(5), 465–474 (1982).
   PubMed Web of Science ®Google Scholar
• Van Houdenhoven K, van Kaam KJ, van Grootheest AC, Salemans TH, Dunselman GA. Uterine perforation in women using a levonorgestrel-releasing intrauterine system. Contraception73(3), 257–260 (2006).
   PubMed Web of Science ®Google Scholar
• Shaamash AH, Sayed GH, Hussien MM, Shaaban MM. A comparative study of the levonorgestrel-releasing intrauterine system Mirena versus the Copper T380A intrauterine device during lactation: breast-feeding performance, infant growth and infant development. Contraception72(5), 346–351 (2005).
   PubMed Web of Science ®Google Scholar
• Grimes DA, Shields WC. Family planning for obese women: challenges and opportunities. Contraception72(1), 1–4 (2005).
   PubMed Web of Science ®Google Scholar
• Abdollahi M, Cushman M, Rosendaal FR. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb. Haemost.89(3), 493–498 (2003).
   PubMed Web of Science ®Google Scholar
• World Health Organization. Improving Access to Quality Care in Family Planning: Medical Eligibility Criteria for Contraceptive Use. (Second Edition). WHO, Geneva, Switzerland, 118 (2000).
   Google Scholar
• World Health Organization. Improving Access to Quality Care in Family Planning: Medical Eligibility Criteria for Contraceptive Use. (Third Edition). WHO, Geneva, Switzerland (2004).
   Google Scholar
• Luukkainen T, Lähteenmäki P. Treatment of menorrhagia by levonorgestrel-relaesing intrauterine device. Immunology36, 261–267 (1992).
   Google Scholar
• Scholten PC. The levonorgestrel IUD: Clinical Performance and Impact on Mestruation. Utrecht, The Netherlands (1989).
   Google Scholar
• Faundes A, Alvarez F, Brache V, Tejada AS. The role of the levonorgestrel intrauterine device in the prevention and treatment of iron deficiency anemia during fertility regulation. Int. J. Gynaecol. Obstet.26(3), 429–433 (1988).
   PubMedGoogle Scholar
• Nilsson CG, Allonen H, Diaz J, Luukkainen T. Two years’ experience with two levonorgestrel-releasing intrauterine devices and one copper-releasing intrauterine device: a randomized comparative performance study. Fertil. Steril.39(2), 187–192 (1983).
   PubMedGoogle Scholar
• Barrington JW, Bowen-Simpkins P. The levonorgestrel intrauterine system in the management of menorrhagia. Br. J. Obstet. Gynaecol.104(5), 614–616 (1997).
   PubMedGoogle Scholar
• Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. Contraception49(1), 56–72 (1994).
   PubMed Web of Science ®Google Scholar
• Sivin I, Stern J. Health during prolonged use of levonorgestrel 20 µg/d and the copper TCu 380Ag intrauterine contraceptive devices: a multicenter study. International Committee for Contraception Research (ICCR). Fertil. Steril.61(1), 70–77 (1994).
   PubMed Web of Science ®Google Scholar
• Grigorieva V, Chen-Mok M, Tarasova M, Mikhailov A. Use of a levonorgestrel-releasing intrauterine system to treat bleeding related to uterine leiomyomas. Fertil. Steril.79(5), 1194–1198 (2003).
   PubMed Web of Science ®Google Scholar
• Hurskainen R, Teperi J, Rissanen P et al. Quality of life and cost–effectiveness of levonorgestrel-releasing intrauterine system versus hysterectomy for treatment of menorrhagia: a randomised trial. Lancet357(9252), 273–277 (2001).
   PubMed Web of Science ®Google Scholar
• Hurskainen R, Teperi J, Rissanen P et al. Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia: randomized trial 5-year follow-up. JAMA291(12), 1456–1463 (2004).
   PubMed Web of Science ®Google Scholar
• Vercellini P, Aimi G, Panazza S, De Giorgi O, Pesole A, Crosignani PG. A levonorgestrel-releasing intrauterine system for the treatment of dysmenorrhea associated with endometriosis: a pilot study. Fertil. Steril.72(3), 505–508 (1999).
   PubMed Web of Science ®Google Scholar
• Vercellini P, Frontino G, De Giorgi O, Aimi G, Zaina B, Crosignani PG. Comparison of a levonorgestrel-releasing intrauterine device versus expectant management after conservative surgery for symptomatic endometriosis: a pilot study. Fertil. Steril.80(2), 305–309 (2003).
   PubMed Web of Science ®Google Scholar
• Fedele L, Bianchi S, Zanconato G, Portuese A, Raffaelli R. Use of a levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis. Fertil. Steril.75(3), 485–488 (2001).
   PubMed Web of Science ®Google Scholar
• Lockhat FB, Emembolu JO, Konje JC. The efficacy, side-effects and continuation rates in women with symptomatic endometriosis undergoing treatment with an intra-uterine administered progestogen (levonorgestrel), a 3-year follow-up. Hum. Reprod.20(3), 789–793 (2005).
   PubMed Web of Science ®Google Scholar
• Petta CA, Ferriani RA, Abrao MS et al. Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis. Hum. Reprod.20(7), 1993–1998 (2005).
   PubMed Web of Science ®Google Scholar
• Fedele L, Bianchi S, Raffaelli R, Portuese A, Dorta M. Treatment of adenomyosis-associated menorrhagia with a levonorgestrel-releasing intrauterine device. Fertil. Steril.68(3), 426–429 (1997).
   PubMed Web of Science ®Google Scholar
• Fong YF, Singh K. Medical treatment of a grossly enlarged adenomyotic uterus with the levonorgestrel-releasing intrauterine system. Contraception60(3), 173–175 (1999).
   PubMed Web of Science ®Google Scholar
• Nilsson CG, Luukkainen T, Arko H. Endometrial morphology of women using a d-norgestrel-releasing intrauterine device. Fertil. Steril.29(4), 397–401 (1978).
   PubMed Web of Science ®Google Scholar
• Silverberg SG, Haukkamaa M, Arko H, Nilsson CG, Luukkainen T. Endometrial morphology during long-term use of levonorgestrel-releasing intrauterine devices. Int. J. Gynecol. Pathol.5(3), 235–241 (1986).
   PubMed Web of Science ®Google Scholar
• Raudaskoski TH, Lahti EI, Kauppila AJ, Apaja-Sarkkinen MA, Laatikainen TJ. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses. Am. J. Obstet. Gynecol.172(1Pt 1), 114–119 (1995).
   PubMed Web of Science ®Google Scholar
• Gardner FJ, Konje JC, Abrams KR et al. Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: a randomised controlled trial. Lancet356(9243), 1711–1717 (2000).
   PubMed Web of Science ®Google Scholar
• Ronnerdag M, Odlind V. Health effects of long-term use of the intrauterine levonorgestrel-releasing system. A follow-up study over 12 years of continuous use. Acta Obstet. Gynecol. Scand.78(8), 716–721 (1999).
   PubMed Web of Science ®Google Scholar
• Backman T, Huhtala S, Blom T, Luoto R, Rauramo I, Koskenvuo M. Length of use and symptoms associated with premature removal of the levonorgestrel intrauterine system: a nation-wide study of 17,360 users. Br. J. Gyaecol.107(3), 335–339 (2000).
   Google Scholar
• Haukkamaa M, Stranden P, Jousimies-Somer H, Siitonen A. Bacterial flora of the cervix in women using an intrauterine device. Contraception36(5), 527–534 (1987).
   Google Scholar
• Zhou L, Harrison-Woolrych M, Coulter DM. Use of the New Zealand Intensive Medicines Monitoring Programme to study the levonorgestrel-releasing intrauterine device (Mirena). Pharmacoepidemiol. Drug Saf.12(5), 371–377 (2003).
   PubMed Web of Science ®Google Scholar
• Rogovskaya S, Rivera R, Grimes DA et al. Effect of a levonorgestrel intrauterine system on women with Type 1 diabetes: a randomized trial. Obstet. Gynecol.105(4), 811–815 (2005).
   PubMed Web of Science ®Google Scholar
• Backman T, Rauramo I, Jaakkola K et al. Use of the levonorgestrel-releasing intrauterine system and breast cancer. Obstet. Gynecol.106(4), 813–817 (2005).
   PubMed Web of Science ®Google Scholar
• Pakarinen P, Luukkainen T. Five years’ experience with a small intracervical/intrauterine levonorgestrel-releasing device. Contraception72(5), 342–345 (2005).
   PubMed Web of Science ®Google Scholar
• Wu S, Hu J, Wildemeersch D. Performance of the frameless GyneFix and the TCu380A IUDs in a 3-year multicenter, randomized, comparative trial in parous women. Contraception61(2), 91–98 (2000).
   PubMed Web of Science ®Google Scholar
• Wildemeersch D, Janssens D, Vrijens M, Weyers S. Ease of insertion, contraceptive efficacy and safety of new T-shaped levonorgestrel-releasing intrauterine systems. Contraception71(6), 465–469 (2005).
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA288(3), 321–333 (2002).
   PubMed Web of Science ®Google Scholar
• Luukkainen T. Issues to debate on the Women’s Health Initiative: failure of estrogen plus progestin therapy for prevention of breast cancer risk. Hum. Reprod.18(8), 1559–1561 (2003).
   PubMedGoogle Scholar
• Lundström E, Soderqvist G, Svane G et al. Digitized assessment of mammographic breast density in patients who received low-dose intrauterine levonorgestrel in continuous combination with oral estradiol valerate: a pilot study. Fertil. Steril.85(4), 989–995 (2006).
   PubMed Web of Science ®Google Scholar